Trial · NCT02674854
Adverse events57
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 57
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Conjunctival Hyperaemia | Eye disorders | PG324 Ophthalmic Solution | 126 | 244 | 126 |
| other | Conjunctival Hyperaemia | Eye disorders | Netarsudil (AR-13324) Ophthalmic Solution 0.02% | 102 | 255 | 102 |
| other | Conjunctival Hyperaemia | Eye disorders | Latanoprost Ophthalmic Solution 0.005% | 51 | 251 | 51 |
| other | Cornea Verticillata | Eye disorders | PG324 Ophthalmic Solution | 32 | 244 | 32 |
| other | Cornea Verticillata | Eye disorders | Netarsudil (AR-13324) Ophthalmic Solution 0.02% | 25 | 255 | 25 |
| other | Cornea Verticillata | Eye disorders | Latanoprost Ophthalmic Solution 0.005% | 0 | 251 | 0 |
| other | Conjunctival Haemorrhage | Eye disorders | PG324 Ophthalmic Solution | 14 | 244 | 14 |
| other | Conjunctival Haemorrhage | Eye disorders | Netarsudil (AR-13324) Ophthalmic Solution 0.02% | 17 | 255 | 17 |
| other | Conjunctival Haemorrhage | Eye disorders | Latanoprost Ophthalmic Solution 0.005% | 2 | 251 | 2 |
| other | Corneal Disorder | Eye disorders | PG324 Ophthalmic Solution | 14 | 244 | 14 |
| other | Corneal Disorder | Eye disorders | Netarsudil (AR-13324) Ophthalmic Solution 0.02% | 12 | 255 | 12 |
| other | Corneal Disorder | Eye disorders | Latanoprost Ophthalmic Solution 0.005% | 0 | 251 | 0 |
| other | Instillation Site Pain | General disorders | PG324 Ophthalmic Solution | 42 | 244 | 42 |
| other | Instillation Site Pain | General disorders | Netarsudil (AR-13324) Ophthalmic Solution 0.02% | 23 | 255 | 23 |
| other | Instillation Site Pain | General disorders | Latanoprost Ophthalmic Solution 0.005% | 15 | 251 | 15 |
| other | Instillation Site Discomfort | General disorders | PG324 Ophthalmic Solution | 15 | 244 | 15 |
| other | Instillation Site Discomfort | General disorders | Netarsudil (AR-13324) Ophthalmic Solution 0.02% | 16 | 255 | 16 |
| other | Instillation Site Discomfort | General disorders | Latanoprost Ophthalmic Solution 0.005% | 2 | 251 | 2 |
| other | Vital Dye Staining Cornea Present | Investigations | PG324 Ophthalmic Solution | 8 | 244 | 8 |
| other | Vital Dye Staining Cornea Present | Investigations | Netarsudil (AR-13324) Ophthalmic Solution 0.02% | 13 | 255 | 13 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02674854/events